IRMA 2 2001

1 Treatments

Studied treatment  irbesartan 150 mg daily or 300 mg daily

Control treatment  placebo

Concomittant treatments  -

female (%)  -

Diabetic (%)  -

withdrawals  -

mean dose  -

target blood pressure  -

2 Patients

Patients  hypertensive patients with type 2 diabetes and microalbuminuria

Inclusion criteria  -

Exclusion criteria  -

SBP (mmHg)  -

DBP (mmHg)  -

3 Methods

Blinding  double-blind

Design  Parallel groups

Centers  -

Geographical area  multinational

Sizes  404/207
## 4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>cancer occurrence (prespecified endpoint)</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cancer death</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>PAS inférieure à 140</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>PAD inférieure à 90</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>PA inférieure à 140/90</td>
<td>-/404</td>
<td>-/207</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Cardiovascular death</td>
<td>-/404</td>
<td>-/207</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>stroke (fatal and non fatal)</td>
<td>-/404</td>
<td>-/207</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Myocardial infarction (fatal and non fatal)</td>
<td>5/404</td>
<td>5/207</td>
<td>0,51</td>
<td>[0,15; 1,79]</td>
</tr>
<tr>
<td>Heart failure</td>
<td>-/404</td>
<td>-/207</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cardiac death</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all cause death</td>
<td>11/404</td>
<td>5/207</td>
<td>1,13</td>
<td>[0,39; 3,29]</td>
</tr>
<tr>
<td>coronary event</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cardiovascular event</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cardiovascular death</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>apparition d’un premier événement cardiovasculaire</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>New onset diabetes</td>
<td>-/404</td>
<td>-/207</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>prostate cancer</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cancer</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cancer occurrence</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>lung cancer</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>breast cancer</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

## 5 References